Who Owns Dupixent?

Dupixent operates under the joint sustainability frameworks of Sanofi and Regeneron Pharmaceuticals. Both companies have committed to reducing carbon emissions and implementing energy-efficient biomanufacturing processes at their facilities.

Manufacturing Environmental Impact: Dupixent manufacturing uses Chinese hamster ovary (CHO) cells in large-scale bioreactors at facilities in Rensselaer, New York; Germany; and France. Both companies have optimized these processes to reduce water usage, energy consumption, and waste generation. Sanofi has set carbon neutrality targets for its operations, and Regeneron has invested in renewable energy and energy-efficient equipment at its manufacturing sites.

Clinical Trial Ethics: The Dupixent clinical development program has enrolled tens of thousands of patients across multiple Phase 3 trials. Both companies publish trial results in peer-reviewed journals including the New England Journal of Medicine, The Lancet, and JAMA. The companies have faced questions about diversity in clinical trial enrollment, particularly regarding representation of racial and ethnic minorities in atopic dermatitis and asthma trials.

Patient Access Programs: Sanofi and Regeneron offer co-pay assistance programs for eligible U.S. patients and have established patient access schemes in developing markets. However, the drug's high cost remains a barrier. Annual treatment costs in the United States typically exceed $30,000 before rebates and insurance. Patient advocacy groups have criticized the pricing, particularly given the large and growing patient population dependent on the drug for chronic conditions.

Pipeline Ethics: Sanofi has been publicly preparing for Dupixent's patent expiration, which is expected in the late 2020s to early 2030s. The company's strategy includes launching new products to replace potential revenue loss. Critics have questioned whether this strategy prioritizes shareholder returns over patient access, particularly if biosimilar entry is delayed through patent litigation.

Dupixent has received recognition primarily for therapeutic advancement rather than brand marketing. Key recognitions include:

• FDA Breakthrough Therapy Designation: Dupixent received FDA Breakthrough Therapy designation for several indications during its development, including atopic dermatitis and EoE, recognizing its potential to treat serious conditions with unmet medical need.
• First Biologic Approved for COPD (2024): The FDA approval of Dupixent for COPD in September 2024 was recognized as a landmark in respiratory medicine. No biologic had previously been approved for COPD, which is the third leading cause of death worldwide.
• Galen Prize (2017): Dupixent was awarded the Galen Prize in the Best Pharmaceutical Product category in 2017, recognizing it as the most innovative pharmaceutical product launched that year.
• Published Clinical Research: Dupixent Phase 3 trial results have been published in the New England Journal of Medicine, The Lancet, JAMA, and other leading medical journals across all approved indications.
• Scrip Awards: The Sanofi-Regeneron collaboration on Dupixent has been recognized at Scrip Intelligence pharmaceutical industry awards for partnership excellence and product launch performance.

Dupixent has faced relatively few major safety controversies compared to many blockbuster drugs, but several issues have drawn scrutiny.

Pricing and Access Concerns: Annual treatment costs exceeding $30,000 in the U.S. have drawn criticism from patient advocacy groups, healthcare systems, and policymakers. The Institute for Clinical and Economic Review (ICER) has published health technology assessments questioning whether Dupixent's price aligns with its clinical value. Both Sanofi and Regeneron offer patient assistance programs, but gaps in coverage remain for uninsured and underinsured patients.

Insurance Coverage Barriers: Some payers have implemented prior authorization requirements or step therapy protocols that require patients to try and fail cheaper alternatives before Dupixent is approved. These policies can delay treatment for months, particularly for atopic dermatitis and asthma patients. Patient advocacy groups have pushed back against these restrictions, arguing that Dupixent's safety profile justifies broader access.

Patent and Biosimilar Disputes: As Dupixent's patents approach expiration in the late 2020s and early 2030s, Sanofi and Regeneron have been building patent defenses to delay biosimilar entry. Critics argue that patent thickets artificially extend monopoly pricing. Biosimilar manufacturers have begun developing dupilumab copies, though none have received FDA approval as of 2025.

Side Effects: Dupixent is generally well-tolerated, but the FDA label includes warnings for conjunctivitis, injection site reactions, and hypersensitivity reactions. A boxed warning is not required. Some patients have reported eye inflammation severe enough to require discontinuation. Post-marketing surveillance continues to monitor for rare adverse events.

Clinical Trial Diversity: The Dupixent clinical trial program has faced criticism regarding the racial and ethnic diversity of enrolled patients. Several Phase 3 trials had majority white patient populations, raising questions about how well the results generalize to other demographic groups. Both companies have stated commitments to improve diversity in ongoing and future trials.

No Product Recalls: As of August 2025, Dupixent has not been subject to any FDA-mandated product recalls. Manufacturing quality has been maintained across all production sites.